# Breathe Biomedical — Healthcare Investment Intelligence

> diagnostics. MedFuel Intel profile as of 2026-06-12.

Breathe BioMedical is developing a breath analytics platform technology using infrared spectroscopy and machine learning to detect biomarkers for early-stage breast cancer, particularly in women with dense breast tissue, with a recent study showing 88.2% accuracy unaffected by breast density.[1][2][4]

## Key facts (as of 2026-06-12)
- Sector: diagnostics
- Website: https://breathebiomedical.com/

## MedFuel assessment
- Intelligence score: 25/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/breathe-biomedical. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.